6:10 PM
 | 
Jan 07, 2013
 |  BC Extra  |  Clinical News

Boehringer, Lilly report Phase III data for SGLT2 inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) and partner Eli Lilly and Co. (NYSE:LLY) said once-daily empagliflozin met the primary endpoint of reducing HbA1c from baseline to 24 weeks vs....

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >